Enterprise Therapeutics Ltd. has raised £26m for the Phase IIa trial of ETD001, a novel cystic fibrosis treatment, with investment led by Panakes Partners and participation from existing investors.
Tag Archive for: Drug development
Antibody engineering?The development of therapeutic antibodies is a time and cost intensive process. Biological and physicochemical properties of the lead molecules influence almost every step in the development. Investing into antibody engineering and lead optimisation during early development pays off in later steps and does not only accelerate the programme, but also increases the chance of success.
EpiEndo Pharmaceuticals ehf got the green light for a Phase IIa COPD trial with its non-anbibiotic macrolide EP395
Jolt Capital contributed $20m to the BC Platforms’ data footprint expansion on November 8th.